HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Survey Shows US Voters Have Message For FDA And Congress About OTC Birth Control

Executive Summary

Data For Progress survey of 1,252 likely voters found “overwhelmingly support” from Democrats and Republicans for women’s access to daily oral contraceptives without a prescription and for FDA to allow OTC access.

You may also be interested in...



Limiting Reproductive Rights Has US Consumers Searching For OTC Access To Birth Control

Fractl looked into online OTC birth control searches for HBW Insight after initially focusing on interest in male birth control options since the Supreme Court’s ruling in Dobbs vs. Jackson.

HRA Proposes OTC Norgestrel Birth Control

HRA has worked with Ibis Reproductive Health, which supports the Free the Pill advocacy group, to conduct research for a norgestrel switch NDA.

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Perrigo's HRA Pharma submits to FDA on 11 July an NDA by for OTC 0.075-mg norgestrel, branded Opill, The same formulation previously was available Rx 30 years. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS152698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel